<DOC>
	<DOCNO>NCT00876109</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I , dose-escalation study ass safety , tolerability , pharmacokinetics orally administer GDC-0941 administer daily ( QD ) twice daily ( BID ) treatment advance metastatic solid tumor .</brief_summary>
	<brief_title>A Study GDC-0941 Participants With Locally Advanced Metastatic Solid Tumors Which Standard Therapy Either Does Not Exist Has Proven Ineffective Intolerable</brief_title>
	<detailed_description />
	<criteria>Participants histologically document , incurable , locally advanced metastatic solid malignancy progress failed respond least one prior regimen , candidate regimens know provide clinical benefit Evaluable measurable disease per RECIST Life expectancy great equal ( &gt; /= ) 12 week Documented willingness use effective mean contraception ( men woman ) participate study Leptomeningeal disease manifestation current malignancy History Type 1 2 diabetes mellitus require regular medication Any condition require anticoagulant , warfarin , heparin , thrombolytic Malabsorption syndrome condition would interfere enteral absorption Known untreated central nervous system ( CNS ) malignancy treat brain metastasis radiographically stable &gt; /=3 month Active congestive heart failure ventricular arrhythmia require medication Uncontrolled ascites require weekly largevolume paracentesis 3 consecutive week prior enrollment Active infection require intravenous ( IV ) antibiotic Requirement daily supplemental oxygen Uncontrolled hypomagnesemia hypokalemia , define value low limit normal ( LLN ) , hypercalcemia upper limit normal ( ULN ) institution despite adequate electrolyte supplementation management Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Known human immunodeficiency virus ( HIV ) infection Any disease , active uncontrolled pulmonary dysfunction , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render participant high risk treatment complication Significant traumatic injury within 3 week Day 1 Major surgical procedure within 4 week prior initiation study treatment Treatment chemotherapy , hormonal therapy ( except gonadotropin release hormone [ GnRH ] agonists antagonist prostate cancer ) , immunotherapy , biologic therapy , radiation therapy ( except palliative radiation bony metastasis ) cancer therapy within 4 week prior initiation study treatment Palliative radiation bony metastasis within 2 week prior initiation study treatment Need chronic corticosteroid therapy great ( &gt; ) 7 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Metastatic Solid Tumors</keyword>
	<keyword>PI3K</keyword>
	<keyword>PI3K Inhibitors</keyword>
</DOC>